Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab.

PURPOSE Erb-B2 receptor tyrosine kinase 2 (ERBB2)-positive breast cancer (BC) is particularly common in young women. Genomic features of ERBB2-positive tumors before and after chemotherapy and trastuzumab (chemo + H) have not been described in young women and are important for guiding study of therapeutic resistance in this population. METHODS From a large prospective cohort of women age 40 years or younger with BC, we identified patients with ERBB2-positive BC and tumor tissue available before and after chemo + H. Whole-exome sequencing (WES) was performed on each tumor and on germline DNA from blood. Tumor-normal pairs were analyzed for mutations and copy number (CN) changes. RESULTS Twenty-two women had successful WES on samples from at least one time point; 12 of these had paired sequencing results from before and after chemo + H and 10 had successful sequencing from either time point. TP53 was the only significantly recurrently mutated gene in both pre- and post-treatment samples. MYC gene amplification was observed in four post-treatment tumors. Seven of 12 patients with paired samples showed acquired and/or clonally enriched alterations in cancer-related genes. One patient had an increased clonality putative activating mutation in ERBB2. Another patient acquired a clonal hotspot mutation in TP53. Other genomic changes acquired in post-treatment specimens included alterations in NOTCH2, STIL, PIK3CA, and GATA3. There was no significant change in median ERBB2 CN (20.3 v 22.6; Wilcoxon P = .79) between paired samples. CONCLUSION ERBB2-positive BCs in young women displayed substantial genomic evolution after treatment with chemo + H. Approximately half of patients with paired samples demonstrated acquired and/or clonally enriched genomic changes in cancer genes. ERBB2 CN changes were uncommon. We identified several genes warranting exploration as potential mechanisms of resistance to therapy in this population.

[1]  M. Pistelli,et al.  Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer , 2022, Breast.

[2]  Amanda R. Kulick,et al.  HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway , 2021, Nature Communications.

[3]  Zishan Wang,et al.  Genomic and molecular features distinguish young adult cancer from later-onset cancer , 2021, Cell reports.

[4]  R. Tamimi,et al.  Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer , 2021, British Journal of Cancer.

[5]  S. Gardiner,et al.  Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes , 2021, Journal of surgical oncology.

[6]  C. Omarini,et al.  Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy , 2020, Translational oncology.

[7]  F. Couch,et al.  The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort , 2020, Journal of the National Cancer Institute.

[8]  Li Ding,et al.  CharGer: clinical Characterization of Germline variants , 2018, Bioinform..

[9]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[10]  A. Howell,et al.  Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens , 2016, Breast Cancer Research and Treatment.

[11]  R. Bose,et al.  HER2 missense mutations have distinct effects on oncogenic signaling and migration , 2015, Proceedings of the National Academy of Sciences.

[12]  A. McKenna,et al.  Paired Exome Analysis of Barrett’s Esophagus and Adenocarcinoma , 2015, Nature Genetics.

[13]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[14]  C. Perou,et al.  c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer , 2014, Oncogene.

[15]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[16]  Trevor J Pugh,et al.  Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation , 2013, Nucleic acids research.

[17]  D. Rahardja,et al.  Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer , 2012, British Journal of Cancer.

[18]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[19]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[20]  Dennis C. Friedrich,et al.  A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries , 2011, Genome Biology.

[21]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[22]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[23]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[24]  R. Gray,et al.  Are HER2-positive breast cancer and BRCA mutation-associated breast cancer mutually exclusive diseases? Evidence from the Mayo Clinic Arizona Cohort. , 2010 .

[25]  Zhaoxia Yu,et al.  Simultaneous genotype calling and haplotype phasing improves genotype accuracy and reduces false-positive associations for genome-wide association studies. , 2009, American journal of human genetics.

[26]  A. Jakubowska,et al.  Estrogen receptor status in CHEK2‐positive breast cancers: implications for chemoprevention , 2009, Clinical genetics.

[27]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[28]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[29]  E. Perez,et al.  Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer , 2007 .

[30]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[31]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..